INTRODUCTION
Spontaneous dyskinetic (or abnormal) movements have been associated with schizophrenia (or to some subforms) independently of the use of antipsychotics. It has been suggested that some forms of dyskinesia may at least partially be intrinsic to the pathophysiology of schizophrenia, perhaps reflecting basal ganglia pathology. However, up to 50% of patients affected with schizophrenia typically develop dyskinesia in combination with long-term exposure (ie months to years) of traditional or 'typical' antipsychotics. The term tardive dyskinesia (TD) refers to this potentially irreversible complication that is, by definition, caused by the long-term use of antipsychotic medication. TD consists of hyperkinetic involuntary movements, most commonly characterized by orofacial dyskinesia, but it may include tics, chorea and/or athetosis or a combination of these. 1 For obvious reasons, TD may be extremely distressing to patients as it substantially debilitates motor performances in normal life. Furthermore, TD may lead to social stigmatization or to difficulties in finding employment. The presence of schizophrenia is not necessary to develop antipsychotic induced dyskinesias, as these occur also in patients treated with antipsychotics for other conditions than schizophrenia. A meta-analysis including 76 studies on 39 187 patients with chronic antipsychotic treatment reported TD rates that ranged from 3 to 70% and an overall prevalence of 24.2%. 2 Prevalence rates are, however, difficult to estimate because of the fluctuating course of TD and heterogeneities across studies with respect to study population, diagnostic criteria used, type and dose of (co-)medications, etc. Age, regardless of the duration of treatment, is an important risk factor for TD, as TD is five to six times more prevalent in the elder (445 years) than in younger patients. 3, 4 Even though newer (or 'atypical') antipsychotics have a lower or perhaps negligible risk to induce TD, 5 classical (or typical) antipsychotics are, however, currently still prescribed for many reasons: Typical antipsychotics are less expensive than atypical antipsychotics, which may globally be one leading reason. Moreover, some patients do not respond or tolerate treatment with atypical antipsychotics that may cause side effects as weight gain or diabetes mellitus. Finally, if patients are treated by intramuscular application of antipsychotics (ie with depot formula), this particular pharmacopeia is mostly composed of classical antipsychotics. Therefore, TD still represents a serious and prevalent adverse effect. The prevention of TD and the detection of associated risk factors are of great clinical importance as no uniformly safe and effective treatment for TD is available yet.
In this review, we retrieved literature with the use of the computerized database MEDLINE (1966 to July 2003), and abstracts that refer to patient samples that were included in a pooled analysis on the dopamine D3 receptor gene by Lerer et al. 6 We do not refer to findings published earlier than 1995 related to the human leukocyte antigen (HLA) and TD, as we wish to focus on more recent findings. To be complete in our coverage of recent data, we refer to three study findings that have not been published yet, which focus on the CYP1A2, NOS1 and DBH genes (see Table 2 ).
DIAGNOSTIC ASSESSMENT OF TD
One particular problem with studies on TD consists in the difficulties of diagnostic assessment: First of all, dyskinetic movements are not specific to TD and therefore, any other disorder presenting with similar symptoms has to be ruled out by a thorough neuropsychiatric history and a physical examination. Moreover, although dyskinetic movements are visibly obvious signs, TD symptoms may fluctuate considerably over the course of the disorder or may be temporarily 'masked' by some antipsychotics, only to reappear after discontinuation of the drugs. In other cases, TD symptomatology does not follow changes following reduction or increase of antipsychotics. However, it remains unclear whether this variability represents etiologically or pathophysiologically distinct forms of TD. Therefore, there are notable limitations to diagnostic validity and reliability in TD studies. In order to overcome some of these limitations, diagnosis of TD should be based on at least two examinations at different time points and ideally performed by the same investigator. Moreover, standardized symptom rating scales should be applied in TD studies to allow for comparisons among studies.
In previous pharmacogenetic studies on TD, dyskinetic movements have mostly been assessed with the Abnormal Involuntary Movement Scale (AIMS). AIMS scores were often used for cross-sectional, continuous analyses in TD studies or, alternatively, AIMS scores have been used to assign a diagnosis of TD, most commonly according to the criteria for TD proposed by Schooler and Kane. 7 Thus, some authors only performed continuous analysis, while others performed solely categorical analyses. However, the co-existence of both forms of analysis limits the comparisons among different studies.
Importantly, according to Schooler and Kane 7 criteria, a diagnosis of persistent TD requires that TD is observed for 3 months. If observed only on one occasion, TD diagnosis remains 'probable'. However, some studies did not perform TD assessment twice or did not specify whether TD assessment has been done after more than one examination. This further limits interpretation of the findings and comparisons among different studies.
In summary, one has to be aware of these characteristics related to TD diagnosis. Besides other confounding factors such as age, gender or samples (size, duration of illness, antipsychotic treatment, etc), these factors may be the major cause for considerable study heterogeneity and nonreplication across studies.
RISK
FACTORS FOR TARDIVE DYSKINESIA Many efforts have been undertaken to unravel the underlying mechanisms of TD; however, the exact pathophysiology remains largely unknown. Due to the antidopaminergic properties of classical antipsychotics, it has been suggested that an overactivity of dopaminergic neurotransmission, thought to be secondary to chronic blockade of D2-like receptors in the basal ganglia, may play a crucial role in the manifestation of TD. 8 From a clinical point of view, detection of risk factors associated with TD may be of particular interest, as this may help to outweigh the benefit-to-risk ratio during treatment with antipsychotics and further point to specific mechanisms involved in TD. Potential socio-demographical and clinical risk factors associated with TD are summarized in Table 1 . Advanced age (see introduction) and early manifestation of extrapyramidal symptoms are the risk factors which have most consistently been reported. 9 However, many other findings related to risk factors for TD have often been inconsistent (eg gender). Therefore, validity of the assessment of such risk factors remains limited in clinical practice since most of these factors are ubiquitous (or appear to confer only a small amount of risk) with respect to the occurrence of TD. Based on animal and clinical studies, a genetic basis has been suggested in the pathophysiology of TD. In rats, occurrence of repetitive jaw movements and vacuous chewing following administration of antipsychotics showed considerable interindividual variability and varied significantly in different strains of selectively bred rats, suggesting a genetic component in the manifestation of TD. 10, 11 Human evidence supporting genetic factors for TD derive from family studies reporting a higher occurrence of TD in patients with a family history of schizophrenia 12 and/or a significant concordance of TD occurrence (or non-occurrence) in first-degree relatives. 13, 14 Finally, genetic factors have been reported to be involved in extrapyramidal disorders such as dystonia 15 and Parkinson's disease, 16 both of which are characterized by abnormal involuntary movements and hypothetically may share common susceptibility pathways with TD. In summary, although these findings in animals and humans do not directly prove the existence of a genetic component in TD, they provide substantial support. A causal relationship may therefore only be proven by further studies that reveal molecular genetic etiologies. Thus far, molecular genetic findings do in fact support the hypothesis of a genetic basis of TD, as will be highlighted in this review. In addition, molecular genetic studies have reinforced the notion that TD follows a polygenic mode of inheritance, although this aspect is difficult to prove and awaits confirmation through further studies. Table 2 . [19] [20] [21] and to be observed as a trend in other studies; [22] [23] [24] [25] [26] however, some have failed to detect this trend. [27] [28] [29] [30] These mixed results are likely due to considerable study heterogeneity with regard to the gene variants examined, type and amount of medication, study sample (ie age, ethnicity), use of different rating scales for the assessment of dyskinetic movements, etc. Another shortcoming is the limited sample size of most studies: For example, some CYPD26 variants were observed only at low frequencies and therefore many findings may have only limited statistical power, leading to type II errors. Despite these limitations, it seems that allelic variation leading particularly to poor metabolism of antipsychotics might confer an increased risk for TD, although the effect size is small and likely depends on particular co-factors such as ethnicity or smoking.
Besides the CYP2D6 enzyme, other P450 enzymes are very active participants in the metabolism of many antipsychotics as well. The CYP1A2 gene has received attention in this context as two single-nucleotide polymorphisms (SNPs) have been reported to be associated with reduction of the CYP1A2 enzyme activity in smokers: Smoking usually induces CYP1A2 activity, which in turn reduces the plasma concentration of antipsychotic drugs and may therefore limit adverse effects. However, smokers carrying the C/C genotype of the 734C/A variant or the A-allele of the À2964 variant show a significant lower CYP1A2 induction. 31, 32 . One study by Basile et al 33 could demonstrate a significant association between higher AIMS scores (more severe TD) and the C/C genotype of the 734C/A variant with an even more pronounced effect in smokers. However, the significant predictive finding for the 734C/A variant could not be replicated in three larger samples of German, 34 Chinese 35 and Japanese 36 patients, all of which included patients' smoking status in their analyses. Inspection of the genotype data, however, reveals a trend in each of the three studies in the same direction as the finding of Basile et al. 33 Furthermore, the frequency of homozygous C/C patients was too low (B9-12%) in the three subsequent studies, [34] [35] [36] to have power to detect the size of effect observed by Basile et al, 33 who found a higher frequency of the C/C genotype (B18%). In this study of Basile et al, 33 the frequency of the C/C homozygotes was highest in the African-American subpopulation, thus providing a likely explanation as to why the C/C rate was higher in that sample. The study by Matsumoto et al 36 combined their analyses of the 734C/A variant with the -2694G/A variant, in order to perform haplotype analyses. However, they could not detect any association with TD. Finally, Segman et al 37 found an association between homozygosity for a gene variant in the CYP17a-hydroxylase in presence of the DRD3Gly allele and the highest orofacial, distal and incapacitation AIMS scores. This exploratory finding merits further replication in larger samples; however, the approach to detect interactive effects among different gene variants appears promising.
The Dopaminergic System
Due to the postsynaptic dopamine supersensitivity hypothesis of TD, the dopaminergic system has received marked attention in TD studies.
The underlying hypothesis in pharmacogenetic studies is based on a pharmacodynamic principle, in that dopamine receptor variants may modulate the signaling pathways of antipsychotics that may lead to susceptibility for TD. However, studies related to DRD2 have been inconclusive. Only Chen et al 38 found an association between the TaqI A polymorphism with TD in females, and Hori et al 39 found a weak association with the À141C Ins/del variant and TD, which did not remain significant with subsequent regression analysis. Three other studies did not reveal a significant association. [40] [41] [42] As for the dopamine D3 receptor gene, DRD3 knockout mice show locomotor hyperactivation similar to those in TD, thus implicating a potential role for the DRD3 in the etiology of TD. In contrast to the findings on DRD2, one polymorphism of the DRD3 gene (Ser9Gly) has more consistently been shown to be associated with TD, although results were mixed among studies (see Table 2 ). In order to shed light on these controversial results, recently, Lerer et al 6 performed a combined analysis including data from 780 patients from six research centers, dividing patients into eight groups based on their population origin. Most of the data have been published previously either in peer reviewed journals [43] [44] [45] [46] [47] or in abstract form 48, 49 (see Table 2 for more details). The authors applied stepwise logistic regression, and confounding effects of group, age and gender were taken into account. In a subset of patients, AIMS scores were used as a continuous variable as opposed to a dichotomous one (TD-yes vs TD-no). Overall, the DRD3 Gly allele carrier status and the Gly/Gly genotype were found to be significantly associated with TD or 1.04-1.70) . Thus, the results of these analyses support a small, but significant contribution of the DRD3 Ser9Gly polymorphism to TD susceptibility. One early study by Gaitonde et al, 52 reporting no association between movement disorders (including TD, catatonic and Parkinsonian features) and the DRD3 Ser9Gly polymorphism in schizophrenia patients, was not included in the meta analysis by Lerer et al. 6 However, the lack of a thorough TD assessment may be one major cause for this negative finding and suggests that the polymorphism is rather associated with TD per se and not in a wider array of unspecific movement disorders. More recently, Woo et al 53 found a significant association between the Gly/Gly genotype and TD, thus also supporting the role of the DRD3 Ser9Gly variant in the Korean population. However, Chong et al 42 found no significant association with the Ser9Gly variant in a Chinese sample, but found an opposite finding in logistic regression analysis for the Ser/Ser genotype being associated with TD. Possible explanations may include that the Ser9Gly polymorphism is not the causative genetic site, but may be in linkage disequilibrium with the causative risk allele only in certain ethnic groups, not including Chinese patients. Finally, the DRD3 gene may be associated with a subgroup of schizophrenia presenting with a subset of specific symptoms and predisposition to TD, as suggested by Segman and Lerer. 54 Further analyses are needed to elucidate the role of the DRD3 gene in TD with respect to clinical features.
One gene variant in the dopamine transporter was analyzed for TD in a Japanese population, yielding negative results. 40 Recently, our group has investigated the potential relationship between the dopamine beta-hydroxylase (DBH) gene (TaqI variant in intron 5), which has previously been reported to be associated with attention deficit hyperactivity disorder (ADHD). 55 However, no association could be detected (De Luca and Kennedy, unpublished data).
The Serotonergic System
As many antipsychotics are thought to modulate serotonergic (5-HT) receptors interacting with dopaminergic neurotransmission, 5-HT receptor genes have been considered as reasonable candidates as well. An initial finding by Segman et al 56 suggested that, for the 5-HT2A gene, the 102C allele and 102CC genotype are associated with TD, specifically with higher AIMS trunk dyskinesia scores. Although Tan et al 57 found a much lower frequency of the C-allele in their sample, their findings were consistent with Segman et al, 56 as they reported a significant excess of the T allele and T/T genotype with non-occurrence of TD. Basile et al 58 and Herken et al 59 were unable to replicate these findings and, therefore, the role of the T102C variant in the 5-HT2A gene cannot be unambiguously associated with the occurrence of TD. Segman et al, 60 however, could demonstrate by further analysis that the effect of 5-HT2A in TD is age related: The 5-HT2A variant seems to confer risk for TD in older patients (449 years) but not in younger patients, which may explain the inconsistent findings. Of note, the T102 C and the A-1438G variants were found to be in linkage disequilibrium in the studies of Segman et al 56 and Basile et al; 58 therefore, similar results with both variants were obtained.
Another variant of the 5-HT2A gene did not reveal any significant finding (His452Tyr). 56, 58 The Ser allele of the X-linked 5-HT2C Cys23Ser variant was found to be associated with TD in females. 61 By using stepwise multiple regression analyses, the inclusion of DRD3 genotypes revealed an additive contribution of the 5-HT2C Ser allele and the DRD3 Gly allele, respectively, of 4.2 and 4.7% to the variance of orofacial dyskinesia (OFD) scores in the overall sample. 61 Zhang et al 62 found a significant association (including only males) with the 5-HT2C promoter variant À697C allele, but not with the À759C/T variants or with haplotype analyses. No association has been reported between the 5-HT6 receptor, or the serotonin transporter 59, 63 and TD.
Oxidative Stress-Related Genes Oxidative stress has been implicated in the pathophysiology of TD. Long-term administration of antipsychotics, by blocking dopamine receptors, is known to increase dopamine turnover and to produce free radicals. The latter may be involved in the development of TD through neuronal damage induced by lipid peroxidation. 64, 65 This hypothesis is supported by the finding that increased markers of oxidative stress such as lipid peroxidation products have been found in the cerebrospinal fluid (CSF) of patients with TD. 66, 67 In addition, chronic treatment with antipsychotics caused significant decreased antioxidant enzyme activities in rat brain. 68 Furthermore, several studies have shown the beneficial effect of vitamin E, a free radical scavenger, on TD symptoms. 69 Additionally, increased oxidative stress with cumulative free radical damage is a well-known feature of the aging brain, 70 which is relevant to the predominant risk factor of TD, namely, aging.
Based on the above findings, molecular genetic study of TD has also focused on oxidative stress-related genes. Hori et al 71 have investigated the genetic association between a functional polymorphism (AlaÀ9Val) in the manganese superoxide dismutase (MnSOD) gene and TD in Japanese patients with schizophrenia. In their study, they found decreased À9Ala allele frequency in patients with TD compared to patients without TD, and that the À9Ala allele might play a protective role against TD. Zhang et al 72 have failed to replicate the findings by Hori et al. 71 Nevertheless, they found a significant positive correlation between total AIMS score and MnSOD activity, which may imply MnSOD's role in pathogenesis of TD.
Kimura et al 73 examined the allelic frequencies in apolipoprotein E (ApoE)
Genetics of tardive dyskinesia DJ Müller et al gene in 333 Japanese schizophrenic patients with TD, since ApoE e4 has decreased anti-oxidant activity as measured by cytotoxicity. 74 Although no significant differences in ApoE allelic frequency were found between TD and non-TD groups, ApoE e4 was significantly lower in the female TD group than in the male TD group.
Nitric oxide (NO) has been identified as a nonconventional neurotransmitter as well as one of the free radicals in the CNS. Hence, NO may play a role in the pathophysiology of TD. 75, 76 Production of neuronal NO from Larginine is catalyzed by neuronal NO synthase (NOS1). Shinkai et al 77 have investigated the genetic association between a C/T polymorphism of exon 29 in the NOS1 gene and TD in 171 Japanese patients with schizophrenia including 41 patients with TD. Although the results were negative, more investigations on other populations are warranted.
Other Studies of Genes Potentially Related to TD Opioid receptors were hypothesized to be associated with TD according to findings in animal studies. The m and d opioid receptor gene variants were investigated without detecting significant results, 78 according to Schooler and Kane criteria. 7 However, with the more permissive Glazer and Morgenstern criteria, 9 Ohmori et al found a protective effect with the 118G allele of the m receptor gene. 78 TD risk was found to be higher in females and after the menopause. In addition, estrogens interact with the dopaminergic system and thus Lai et al 79 drew their attention towards two polymorphisms in the estrogen receptor a. However, only a trend was noted in the overall sample. No specific effect was found in females alone. 79 The angiotensin-converting enzyme has been found to modulate dopamine turnover in the striatum. 80 Segman et al 81 examined the role of a functional Ins/Del variant, however, yielding no significant results.
The catechol-o-methyltransferase (COMT) gene is involved in dopaminergic turnover and thus has been hypothesized to be a candidate for TD studies in a study by Herken et al, 59 but an association between the Val158Met variant and TD could not be detected, suggesting that this enzyme does not play a major role in TD. This is also consistent with the finding that COMT plays little role in dopamine turnover in the striatum. 37, 61, 83 . In our sample, the risk alleles of the DRD3 and CYP1A2 genes were found to be highly associated with TD (P ¼ 0.00007) in an additive, co-recessive model of interaction which accounted for 450% of the variance in risk for TD. 83 This prediction was for the patients' AIMS score. The overall model also included the covariates, age, sex, ethnicity and smoking. For comparison, this model has similar predictive power to the traditional test of cardiac enzymes in the emergency room for detecting myocardial infarction. Thus, the question arises: When is a genetic test ready for clinical application? A test for TD risk, even if only explaining part of the risk, may be very valuable to psychiatrists worldwide. Clinicians frequently face the decision as to whether to treat a patient on a newer atypical antipsychotic, which is almost exclusively administered orally, vs a traditional antipsychotic in depot formulation that facilitates compliance particularly in disorganized patients. If the clinician could administer a genetic test that provided information suggesting higher risk for TD in a given patient, then the clinician might shift toward use of atypical antipsychotics. If the genetic test indicated low risk for TD, then the decision might shift toward use of traditional depot antipsychotics which would have greatly increased compliance, lower price and decreased risk for the serious adverse affects of weight gain and diabetes.
However, as there are likely several genes involved in prediction of risk for TD, these genes will need to be defined in terms of their individual as well as interactive effects before an optimal diagnostic test can be developed. In addition, the frequencies of the risk alleles in various ethnic subgroups will need to be ascertained. The sensitivity and specificity of the test needs to be established, and typically this involves piloting the test on thousands of individuals.
If, however, a clinical genetic test for TD is deemed appropriate, then a problem immediately arises. The two genetic variants DRD3 Ser9Gly (Steen et al 43 ) and CYP1A2 C734A (presented in our additive, co-recessive model of interaction as mentioned above) were published (Basile et al 33, 44 ) without
Genetics of tardive dyskinesia DJ Müller et al protecting the potential intellectual property. In our academic culture, it is commonplace to publicize our findings rapidly to promote replication and wide use of the information. Patent protection is not foremost in our minds. Without patent protection on the predictive function of these markers, however, private industry has little or no interest in funding the development of a predictive test. Therefore, and unfortunately for psychiatric patients, the several million dollars required to bring this test into the clinic will be difficult to raise. The costs of development include extensive work in the laboratory to define the test methods rigorously, and largescale pilot screening including various ethnic groups. Only through largescale studies will the sensitivity and specificity of the predictive test be established sufficiently to satisfy regulatory standards.
In conclusion, there are promising findings in genetic studies of TD. Some of these findings appear particularly valid due to extensive replication, and in the case of DRD3, through positron emission tomography. 84 Certainly, other genes may be involved and more work is required. Clearly, the clinical value of a predictive test for TD would be very high. It remains to be seen whether or not the hurdles, including genetic and financial, to the development of such a test can be overcome.
